Penumbra (PEN) Income from Continuing Operations (2014 - 2026)
Penumbra's (PEN) quarterly Income from Continuing Operations came in at $34.8 million in Q2 2026, down 23.16% year-over-year from $45.3 million in Q2 2025, and up 6.76% quarter-over-quarter from $32.6 million in Q1 2026.
Analysis
Penumbra (PEN) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Penumbra (PEN) has reported Income from Continuing Operations for 13 consecutive years, with $34.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income from Continuing Operations fell 23.16% year-over-year to $34.8 million in Q2 2026; TTM through Jun 2026 was $160.5 million, a 8.73% increase from a year earlier, with the FY2025 full-year figure at $177.7 million, up 1168.11% from the prior year.
- Income from Continuing Operations was $34.8 million for Q2 2026 at Penumbra, up from $32.6 million in the prior quarter.
- Over five years, Income from Continuing Operations peaked at $54.2 million in Q4 2023 and troughed at -$60.2 million in Q2 2024.
- A 5-year average of $19.3 million and a median of $24.2 million in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 10725.32% in 2023 and slumped 417.78% in 2024, its largest moves.
- Over 5 years, Income from Continuing Operations stood at $3.9 million in 2022, then jumped by 1298.45% to $54.2 million in 2023, then plunged by 37.88% to $33.7 million in 2024, then surged by 40.56% to $47.3 million in 2025, then decreased by 26.52% to $34.8 million in 2026.
- The last three Income from Continuing Operations figures came in at $34.8 million (Q2 2026), $32.6 million (Q1 2026), and $47.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.86 Bn | 178.25 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 124.18 Bn | 118.97 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 118.18 Bn | 109.36 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 104.54 Bn | 101.07 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.34 Bn | 65.80 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.64 Bn | 45.39 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.93 Bn | 32.47 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.20 Bn | 30.25 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.14 Bn | 20.66 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Penumbra | 12.58 Bn | 11.92 Bn | 264.94 Mn | 34.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.79 Mn |
| Mar 31, 2026 | 32.58 Mn |
| Dec 31, 2025 | 47.34 Mn |
| Sep 30, 2025 | 45.83 Mn |
| Jun 30, 2025 | 45.27 Mn |
| Mar 31, 2025 | 39.22 Mn |
| Dec 31, 2024 | 33.68 Mn |
| Sep 30, 2024 | 29.48 Mn |
| Jun 30, 2024 | -60.17 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Dec 31, 2023 | 54.22 Mn |
| Sep 30, 2023 | 9.20 Mn |
| Jun 30, 2023 | 18.94 Mn |
| Mar 31, 2023 | 8.55 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -3.69 Mn |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | -24.63 Mn |
| Sep 30, 2021 | 8.03 Mn |